Related Experiment Video
Updated: May 7, 2026
14:56
Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
Interface between pharmacotherapy and genes in human obesity
Annalouise O'Connor1, Andrew G Swick
1UNC Chapel Hill Nutrition Research Institute, Kannapolis, N.C., USA.
Human Heredity
|October 2, 2013
Summary
Genetic variations influence how individuals respond to anti-obesity drugs. Understanding this pharmacogenomics can improve weight loss success and drug development for obesity.
Area of Science:
- Pharmacogenomics
- Obesity Research
- Drug Development
Background:
- Obesity is a complex polygenic condition with limited effective long-term treatments.
- Current anti-obesity medications have variable efficacy and safety profiles, creating an unmet medical need.
- Interindividual variability in treatment response necessitates personalized approaches.
Purpose of the Study:
- To review the variability in weight loss response to existing anti-obesity drugs.
- To discuss the association between genetic variation and weight loss outcomes.
- To explore the role of pharmacogenomics in optimizing obesity pharmacotherapy and drug development.
Main Methods:
- Literature review of existing anti-obesity compounds and their efficacy.
- Analysis of pharmacogenomic studies linking genetic variations to weight loss.
- Exploration of successful pharmacogenomics case studies.
Main Results:
- Significant interindividual variability exists in the efficacy of current anti-obesity drugs.
- Genetic factors are associated with differing weight loss outcomes among patients.
- Pharmacogenomics offers a pathway to predict and enhance treatment response.
Conclusions:
- Personalizing anti-obesity medication based on genetic profiles can improve patient outcomes.
- Integrating pharmacogenomics into drug development pipelines can lead to more effective obesity treatments.
- Further research is needed to fully leverage pharmacogenomics for obesity management.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...